| Literature DB >> 33295867 |
Gerald Tegha1, Emily J Ciccone2, Robert Krysiak1, James Kaphatika1, Tarsizio Chikaonda1, Isaac Ndhlovu3, David van Duin2, Irving Hoffman2, Jonathan J Juliano4,5,2, Jeremy Wang6.
Abstract
Antimicrobial resistance (AMR) is a global threat, including in sub-Saharan Africa. However, little is known about the genetics of resistant bacteria in the region. In Malawi, there is growing concern about increasing rates of antimicrobial resistance to most empirically used antimicrobials. The highly drug resistant Escherichia coli sequence type (ST) 131, which is associated with the extended spectrum β-lactamase blaCTX-M-15, has been increasing in prevalence globally. Previous data from isolates collected between 2006 and 2013 in southern Malawi have revealed the presence of ST131 and the blaCTX-M-15 gene in the country. We performed whole genome sequencing (WGS) of 58 clinical E. coli isolates at Kamuzu Central Hospital, a tertiary care centre in central Malawi, collected from 2012 to 2018. We used Oxford Nanopore Technologies (ONT) sequencing, which was performed in Malawi. We show that ST131 is observed more often (14.9% increasing to 32.8%) and that the blaCTX-M-15 gene is occurring at a higher frequency (21.3% increasing to 44.8%). Phylogenetics indicates that isolates are highly related between the central and southern geographic regions and confirms that ST131 isolates are contained in a single group. All AMR genes, including blaCTX-M-15, were widely distributed across sequence types. We also identified an increased number of ST410 isolates, which in this study tend to carry a plasmid-located copy of blaCTX-M-15 gene at a higher frequency than blaCTX-M-15 occurs in ST131. This study confirms the expanding nature of ST131 and the wide distribution of the blaCTX-M-15 gene in Malawi. We also highlight the feasibility of conducting longitudinal genomic epidemiology studies of important bacteria with the sequencing done on site using a nanopore platform that requires minimal infrastructure.Entities:
Keywords: Africa; Escherichia coli; Malawi; antimicrobial resistance; molecular epidemiology; whole genome sequencing
Year: 2021 PMID: 33295867 PMCID: PMC8115906 DOI: 10.1099/mgen.0.000490
Source DB: PubMed Journal: Microb Genom ISSN: 2057-5858
Fig. 1.Distribution of sequence type, specimen type, resistance phenotype and resistance gene composition in 58 Malawian Isolates. Phylogenetic relationship among sequenced isolates with corresponding sequence type, specimen type, phenotypic and genomic AMR status. At the far left is the phylogeny relating these 58 samples with the sequenced from our study as an outgroup (not shown). In line with each terminal branch is the corresponding sample’s sequence type (ST) (‘AMB’ indicates ambiguity in ST assignment), specimen from which the sample was isolated, AMR phenotype (red: resistant, blue: susceptible, purple: intermediate, grey: unknown), and presence of each detected AMR gene in the genome assembly (dark grey: present, light grey: absent, red highlights presence of bla).
Fig. 2.Phylogenetic tree of Malawian isolates. Phylogenetic relationships among the 58 isolates are presented here in relation to previously published Malawi isolates (Table S2). Samples cluster by sequence type, but are well mixed between the two geographically and temporally separated studies. In the left column, blue indicates isolates from this study and grey from the previous study [17]. The rightmost column indicates the MLST where sequence types occurring more than once are assigned a unique colour (all others are left grey).
Sequence data characteristics of all sequenced isolates
|
Sequence data |
Value* |
|---|---|
|
Number of reads |
126 886 (21 843–539 714) |
|
Total bps |
556 Mbp (84–2076 Mbp) |
|
Median fragment size sequenced in sample |
2505 bp (673–4560 bp) |
|
N50 assembly |
4.88 Mbp (0.59–5.37 Mbp) |
|
Number of contigs |
5 (1–43) |
|
Chromosomal median coverage |
106 (15–392) |
*Median (Minimum, Maximum).
Patient characteristics of the 58 included isolates
|
Variable |
Number of isolates n (%) |
|---|---|
|
| |
|
Female |
43 (74) |
|
Male |
15 (26) |
|
|
34 (20–47) |
|
| |
|
Blood |
14 (24) |
|
Urine |
34 (59) |
|
CSF |
2 (3) |
|
Body Fluid |
2 (3) |
|
Joint |
2 (3) |
|
Other |
4 (7) |
|
| |
|
White blood cell count (cells µl−1) |
7.5 (3.8–9.1) |
|
Haemoglobin (g dl−1) |
9.8 (8.4–11.6) |
*Median (IQR); data available for 54 patients.
†Median (IQR); data available for 20 patients.
Kirby–Bauer antimicrobial resistance patterns of included isolates*
|
Drug (Total Tested) |
Susceptible, n (%) |
Intermediate, n (%)† |
Resistant, n (%) |
|---|---|---|---|
|
Amox-Clav (56) |
15 (27) |
9 (16) |
32 (57) |
|
Amoxicillin (58) |
3 (5) |
1 (2) |
54 (93) |
|
Cefotaxime (49) |
21 (43) |
0 (0) |
28 (57) |
|
Ceftriaxone (58) |
25 (43) |
0 (0) |
33 (57) |
|
Chloramphenicol (48) |
29 (60) |
4 (8) |
15 (31) |
|
Ciprofloxacin (58) |
21 (36) |
2 (3) |
35 (60) |
|
Gentamicin (57) |
30 (53) |
0 (0) |
27 (47) |
|
Imipenem (31) |
31 (100) |
0 (0) |
0 (0) |
|
Nalidixic Acid (57) |
17 (30) |
2 (4) |
38 (67) |
|
TMP-SMX (50) |
4 (8) |
1 (2) |
45 (90) |
*Percentage may not equal 100% due to rounding.
†Intermediate susceptibility by Kirby–Bauer test is defined based on a breakpoint that includes isolates with ‘zone diameters within the intermediate range that approach usually attainable blood and tissue levels.’ Response rates may be lower than for susceptible isolates; it implies clinical efficacy in sites where drugs physiologically concentrate or when a higher-than-normal dosage of a drug is used.
Prevalence of AMR genes identified
|
Gene |
Resistance Phenotype |
Isolates, n (%) |
|---|---|---|
|
| ||
|
|
Gentamicin |
11 (19) |
|
|
Gentamicin |
15 (26) |
|
|
Aminoglycoside |
2 (3) |
|
|
Amikacin, kanamycin, tobramycin, quinolone |
1 (2) |
|
|
Streptomycin |
6 (10) |
|
|
Streptomycin |
2 (3) |
|
|
Streptomycin |
34 (59) |
|
|
Streptomycin/spectinomycin |
20 (34) |
|
|
Streptomycin |
5 (9) |
|
|
Kanamycin |
2 (3) |
|
|
Streptomycin |
50 (86) |
|
|
Streptomycin |
50 (86) |
|
|
Streptomycin |
50 (86) |
|
| ||
|
|
Multidrug efflux |
58 (100) |
|
|
Multidrug efflux |
58 (100) |
|
|
Multidrug efflux |
6 (10) |
|
|
Multidrug efflux |
46 (79) |
|
| ||
|
|
Cephalosporin |
6 (10) |
|
|
Cephalosporin |
26 (45) |
|
|
Cephalosporin |
1 (2) |
|
|
Cephalosporin |
1 (2) |
|
|
Cephalosporin |
1 (2) |
|
|
Cephalosporin |
3 (5) |
|
|
Cephalosporin |
1 (2) |
|
|
Cephalosporin |
20 (34) |
|
|
Cephalosporin |
2 (3) |
|
|
Cephalosporin |
23 (40) |
|
|
Cephalosporin |
7 (12) |
|
|
Cephalosporin |
3 (5) |
|
|
β-lactam |
3 (5) |
|
|
β-lactam |
4 (7) |
|
|
Cephalosporin |
21 (36) |
|
|
Cephalosporin |
2 (3) |
|
|
β-lactam |
2 (3) |
|
|
β-lactam |
43 (74) |
|
|
Cephalosporin |
1 (2) |
|
|
β-lactam |
1 (2) |
|
|
β-lactam |
2 (3) |
|
|
β-lactam |
1 (2) |
|
|
β-lactam |
1 (2) |
|
| ||
|
|
Chloramphenicol |
11 (19) |
|
|
Chloramphenicol |
2 (3) |
|
|
Chloramphenicol |
21 (36) |
|
|
Chloramphenicol |
1 (2) |
|
|
Chloramphenicol |
1 (2) |
|
|
Chloramphenicol |
2 (3) |
|
| ||
|
|
Trimethoprim |
2 (3) |
|
|
Trimethoprim |
2 (3) |
|
|
Trimethoprim |
9 (16) |
|
|
Trimethoprim |
1 (2) |
|
|
Trimethoprim |
35 (60) |
|
|
Trimethoprim |
1 (2) |
|
|
Trimethoprim |
4 (7) |
|
|
Trimethoprim |
8 (14) |
|
|
Sulfonamide |
39 (67) |
|
|
Sulfonamide |
51 (88) |
|
|
Sulfonamide |
1 (2) |
|
| ||
|
|
Quinolone |
1 (2) |
|
|
Quinolone |
5 (9) |
|
| ||
|
|
Rifamycin |
2 (3) |
|
|
Rifamycin |
1 (2) |
|
|
Macrolide |
1 (2) |
|
|
Fosfomycin |
1 (2) |
|
|
Macrolide |
37 (64) |
|
|
Macrolide |
1 (2) |
|
|
Quaternary Ammonium |
1 (2) |
|
|
Streptothricin |
2 (3) |
|
|
Tetracycline |
30 (52) |
|
|
Tetracycline |
21 (36) |
Characteristics of CTX-M-15 associated isolates and ceftriaxone disk diffusion results
|
Isolate |
Year Collected |
Source |
Sequence Type (ST) |
Plasmid Inclusion Group(s) |
Disk Diffusion Result |
Location of Gene |
|---|---|---|---|---|---|---|
|
1 |
2018 |
Urine |
131 |
incB/O/K/Z |
R |
Genomic |
|
2 |
2017 |
Blood |
648 |
incF |
R |
Genomic |
|
3 |
2018 |
Urine |
410 |
incF |
R |
Plasmid |
|
5 |
2018 |
Blood |
9398 |
incHI2, incY |
R |
Plasmid |
|
10 |
2018 |
Body Fluid |
410 |
incF |
R |
Plasmid |
|
11 |
2017 |
Urine |
410 |
incF |
R |
Plasmid |
|
12 |
2017 |
Urine |
410 |
incF |
R |
Both |
|
14 |
2014 |
Pus |
410 |
incF, incY |
R |
Plasmid |
|
15 |
2018 |
Urine |
410 |
incF |
R |
Plasmid |
|
18 |
2018 |
Body Fluid |
410 |
incF |
R |
Genomic |
|
22 |
2018 |
Blood |
38 |
incF |
R |
Plasmid |
|
25 |
2014 |
Urine |
131 |
incF |
R |
Genomic |
|
26 |
2014 |
Urine |
131 |
incF |
R |
Plasmid |
|
27 |
2015 |
Urine |
617 |
incF |
R |
Both |
|
28 |
2014 |
Urine |
617 |
incF, incN |
R |
Plasmid |
|
30 |
2016 |
Urine |
131 |
incF |
R |
Genomic |
|
34 |
2016 |
Urine |
410 |
incF |
R |
Plasmid |
|
41 |
2013 |
Blood |
131 |
incN |
R |
Genomic |
|
44 |
2013 |
Urine |
131 |
incF |
R |
Genomic |
|
46 |
2013 |
Urine |
131 |
incF |
R |
Genomic |
|
48 |
2014 |
Blood |
131 |
incF |
R |
Genomic |
|
49 |
2013 |
Blood |
131 |
incF |
R |
Genomic |
|
50 |
2013 |
Joint Fluid |
44 |
incF |
R |
Plasmid |
|
51 |
2013 |
Genital Swab |
131 |
incF |
R |
Both |
|
53 |
2015 |
Blood |
93 |
incI-1I, incF |
R |
Plasmid |
|
54 |
2013 |
Cerebrospinal Fluid |
617 |
incF |
R |
Plasmid |
Prevalence of plasmid incompatibility groups
|
Plasmid Incompatibility Group |
Number of isolates, n (%) |
|---|---|
|
incFII |
26 (45) |
|
incFIA |
19 (33) |
|
incFIB |
15 (26) |
|
incY |
4 (7) |
|
incB/O/K/Z |
2 (3) |
|
incI |
2 (3) |
|
incI1-I |
2 (3) |
|
incN |
2 (3) |
Prevalence of virulence genes identified
|
Category |
Gene |
Isolate, n (%) |
|---|---|---|
|
|
|
58 (100) |
|
|
|
13 (22) |
|
|
|
9 (16) |
|
|
|
19 (33) |
|
|
|
13 (22) |
|
|
|
1 (2) |
|
|
|
21 (36) |
|
|
|
2 (3) |
|
|
|
20 (35) |
|
|
|
1 (2) |
|
|
|
20 (35) |
|
|
|
3 (5) |
|
|
|
1 (2) |
|
|
|
1 (2) |
|
|
|
1 (2) |
|
|
|
23 (40) |
|
|
|
2 (3) |
|
|
|
3 (5) |
|
|
|
6 (10) |
|
|
|
3 (5) |
|
|
|
35 (60) |
|
|
|
9 (16) |
|
|
|
29 (50) |
|
|
|
6 (10) |
|
|
|
8 (13) |
|
|
|
3 (5) |
|
|
|
1 (2) |
|
|
|
6 (10) |
|
|
|
9 (16) |
|
|
|
1 (2) |
|
|
|
23 (40) |
|
|
|
22 (38) |
|
|
|
1 (2) |
|
|
|
6 (10) |
|
|
|
7 (12) |
|
|
|
20 (35) |
|
|
22 (38) |
*This gene is almost universal to E.coli and can be found in non-pathogenic strains.